IMEIK is a leading Chinese biomedical soft tissue repair materials manufacturer.
IMEIK, founded in 2004, has been developed based on the research, development, and transformation of biomedical soft tissue repair materials. The founder is Jian Jun. Listed on the Shanghai Stock Exchange in September 2020, the company's major shareholders are Jian Jun, Ningbo Zhixingjun Investment Management Limited Partnership, and GANNETT PEAK LIMITED. Rivals with the direct and indirect competition with IMEIK include Haohai Biological, Bloomage BioTech.
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
ResearchHealthcare, Technology, Consumer Staples
WIA2020 | Rising Tech Stars 2020: Global & China's 100
ResearchReal Estate, Consumer Discretionary, Industrials
Tech for Global, Globalization Footprints of the Established and the New
AI-driven Biotech Galixir Nominates Preclinical Candidate in Treating Autoimmune Disease
Founded in 2019, Galixir named a Preclinical Candidate (PCC) for the treatment of Autoimmune Disease (AID) which was screened out of around 80 compounds via its proprietary platform, Pyxir®, making it another top-ranking China-based AI-driven drug discovery company.
Jun 21, 2022 01:44 PM
Where Will AI Take Drug Discovery in China to?
The development of drug discovery in China is relatively slower than in many other countries but China’s pharma market size is among the top three worldwide. Deeper exploration of drug discovery is much needed in China. AI can make a machine execute tasks like a human or even better than humans. With many emerging AI-powered drug discovery companies in China, can AI help China beat the pioneers in drug discovery at their own game?
Jun 21, 2022 01:19 PM
ArtechMed Completes Nearly 100 Million CNY in Series C Round
ArtechMed has completed its Series C funding round, which totaled nearly 100 million CNY. 张科禾润基金 led this round of funding, which is followed by 黄埔医药基金 and Sunland Fund. Follow-up investments were also made by Dingxin Capital.
Jun 17, 2022 07:16 PM